PD L1 News and Research

RSS

The role of FOXM1 and PD-L1 in malignant peripheral nerve sheath tumor resistance

A new mini review was published in Oncotarget's Volume 15 on September 30, 2024, entitled, "Linking FOXM1 and PD-L1 to CDK4/6-MEK targeted therapy resistance in malignant peripheral nerve sheath tumors."

1 Oct 2024

Targeting tumor immunity with transferrin receptor-directed photodynamic therapy

This new article publication from Acta Pharmaceutica Sinica B, discusses a transferrin receptor-targeted immunostimulant for photodynamic immunotherapy against metastatic tumors through β-catenin/CREB interruption.

26 Sep 2024

FORT-2 trial shows promising results for bladder cancer immunotherapy combination

Findings from the international FORT-2 clinical trial showed that a combination treatment including immunotherapy is safe and tolerable in patients with locally advanced or metastatic bladder cancer.

19 Sep 2024

Postsurgical treatment with pembrolizumab doubles cancer-free time for bladder cancer patients

Results from a large clinical trial show that treatment with an immunotherapy drug may nearly double the length of time people with high-risk, muscle-invasive bladder cancer are cancer-free following surgical removal of the bladder.

17 Sep 2024

Early data shows mRNA-4359 may benefit patients with advanced solid cancers

Interim data from the Phase I dose escalation part of the mRNA cancer immunotherapy (mRNA-4359), show promise in patients with advanced solid cancers.

16 Sep 2024

Trial finds no benefit of adding nivolumab to tivozanib for advanced kidney cancer

In an international multicenter randomized phase 3 clinical trial led by Dana-Farber Cancer Institute, researchers tested the addition of the immune checkpoint inhibitor (ICI) nivolumab to treatment with tivozanib for patients with advanced clear cell renal cell carcinoma, a form of kidney cancer.

13 Sep 2024

Advances in targeting the CD47/SIRPα "do not eat me" pathway for cancer therapy

A new editorial was recently published in Oncotarget's Volume 15, on July 10, 2024, entitled, "The advances in targeting CD47/SIRPα "do not eat me" axis and their ongoing challenges as an anticancer therapy."

13 Sep 2024

Early Phase I data shows promise for mRNA cancer immunotherapy in advanced solid cancers

Interim data from the Phase I dose escalation part of the mRNA cancer immunotherapy (mRNA-4359), show promise in patients with advanced solid cancers.

12 Sep 2024

Immunotherapy before and after surgery benefits NSCLC patients

People with operable non-small cell lung cancers may fare better over the next few years by receiving immunotherapy treatments before and after surgery instead of only before surgery, according to a new analysis by Johns Hopkins Kimmel Cancer Center investigators.

9 Sep 2024

Ifinatamab deruxtecan shows promising results in advanced small cell lung cancer

The antibody–drug conjugate ifinatamab deruxtecan (I-DXd) showed clinically meaningful responses in pretreated patients with extensive-stage small cell lung cancer (ES-SCLC), according to an interim analysis of the Phase 2 IDeate-Lung01 study.

9 Sep 2024

Auburn University researchers develop AI-driven method to target cancer proteins

Researchers at Auburn University, in collaboration with scientists from the University of Basel and ETH Zurich, have made a groundbreaking advance in the fight against cancer.

5 Sep 2024

Advancing cancer therapy with small molecule immune checkpoint inhibitors

Immunotherapy has revolutionized cancer treatment, with immune checkpoint inhibitors (ICIs) playing a pivotal role.

21 Aug 2024

Advances in precision medicine enhance cancer immunotherapy

The field of precision medicine, especially in the context of cancer immunotherapy, has seen significant advancements in recent years.

20 Aug 2024

EZH2's role in cancer progression and therapy explored

Enhancer of zeste homolog 2 (EZH2) is a catalytic subunit of the Polycomb-repressive complex 2 (PRC2), which plays a crucial role in transcriptional repression through the methylation of histone H3 on lysine 27 (H3K27me3).

9 Aug 2024

Review of fasting-mimicking diets in cancer treatment

Researchers present the role of cyclic fasting and fasting-mimicking diets (FMD) in cancer therapy.

8 Aug 2024

New target identified for melanoma resistant to current therapies

Some proteins, such as programmed cell death protein 1 (PD1), can stop the immune system from attacking cancer cells and, therefore, support the growth of cancer.

6 Aug 2024

FDA accepted PD-L1 inhibitor durvalumab for the treatment of endometrial cancer

On June 14, 2024, the U.S. FDA approved AstraZeneca's Durvalumab (IMFINZI®) for primary advanced or recurrent endometrial cancer with mismatch repair deficiency. Endometrial cancer is the most prevalent gynecologic cancer, with an estimated 66,200 new U.S. cases in 2023.

From Sino Biological Inc. 5 Aug 2024

Researchers discover key functions of IRF1 in cancer progression and treatment response

Investigators at the UCLA Health Jonsson Comprehensive Cancer Center have uncovered new details about the role of a protein called interferon regulatory factor (IRF1) in cancer progression and treatment response, offering new insight that can potentially help improve the effectiveness of cancer immunotherapy.

15 Jul 2024

Researchers identify shared molecular mechanism in cancer and pregnancy that suppresses immune system

Researchers elucidated the shared immune tolerance mechanisms in cancer and pregnancy, focusing on the role of an immune checkpoint protein as an onco-fetal immune tolerance checkpoint.

11 Jul 2024

Advancements in immunotherapy for hepatocellular carcinoma offer hope to patients

Hepatocellular carcinoma (HCC) is a primary liver cancer predominantly arising from chronic liver diseases such as hepatitis B and C infections, alcohol abuse, and metabolic disorders.

2 Jul 2024